Ab­b­Vie con­cedes an­oth­er PhI­II can­cer drug flop as glioblas­toma de­feats lat­est as­sault

One of Ab­b­Vie’s top late-stage can­cer drugs has flopped in a piv­otal tri­al — the lat­est vic­tim to hit bot­tom in the face of glioblas­toma.

The phar­ma gi­ant $AB­BV not­ed Fri­day morn­ing that de­patux­izum­ab mafodotin (or de­patux-m; pre­vi­ous­ly known as ABT-414) has been fail­ing to spark a sur­vival ben­e­fit in EGFR-am­pli­fied cas­es of the com­mon form of brain can­cer in a Phase III study, caus­ing the in­de­pen­dent mon­i­tors to call it off for the an­ti­body-drug con­ju­gate.

An­drew Lass­man­This had been one of Ab­b­Vie’s lead­ing late-stage as­sets in on­col­o­gy, along­side the bit­ter­ly dis­ap­point­ing Ro­va-T, which has ex­pe­ri­enced a se­ries of set­backs. Ab­b­Vie has had con­sid­er­able suc­cess in can­cer with its com­mer­cial prod­ucts and has seen ad­vances with its an­ti-in­flam­ma­to­ries as well. But they took on a tough tar­get when they went af­ter glioblas­toma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER